معرفی
Dr. Mingming Yang is a Visiting Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health. Their research focuses on heart failure subtypes (HFrEF/HFmrEF/HFpEF), clinical outcomes of pharmacotherapies like SGLT2 inhibitors and ARNI, and geographic/age-related disparities in cardiovascular care. Key work includes EuroQol-5D quality of life analyses across HF populations and systematic reviews on cardiac complications in emerging infections. Publications span high-impact journals like JACC: Heart Failure, European Journal of Heart Failure, and Nature Medicine. Current investigations address treatment optimization for elderly HF patients, polypharmacy effects, and regional variations in disease outcomes.
Research emphasizes translational clinical studies involving large-scale trial data (PARADIGM-HF, DAPA-HF, DELIVER). Methodological expertise includes subgroup analysis, win statistics for composite endpoints, and systematic review methodologies. Collaborations involve institutions globally, with particular attention to Asian patient populations and cardiorenal interactions. The work contributes to evidence-based guidelines for HF management and personalized therapeutic approaches.
Key Research Themes:
- Pharmacological management of heart failure subtypes
- Geographic and demographic disparities in cardiovascular outcomes
- Health-related quality of life metrics in chronic disease
- Emerging therapies and patient stratification strategies
Based at the Institute of Cardiovascular & Medical Sciences, Dr. Yang's team investigates both clinical trial data and real-world evidence to improve HF care pathways.